Why the study?
SGLT2 inhibitors improve metabolic and cardiovascular outcomes, but the underlying mechanisms remain incompletely understood.
Does preventive empagliflozin administration attenuate the development of metabolic heart disease in a high-fat, high-sucrose diet mouse model?
Does preventive empagliflozin administration attenuate the development of metabolic heart disease in a high-fat, high-sucrose diet mouse model?
In a mouse model of metabolic heart disease, preventive empagliflozin improves epicardial adipose tissue quality and coronary microvascular function, with benefits mediated in part through macrophage NOS2.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for microvascular benefits in metabolic cardiomyopathy models; human trials needed before preventive use.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve metabolic and cardiovascular outcomes, but the mechanisms remain incompletely understood. We utilized cardiovascular magnetic resonance (CMR) and complementary methods to investigate whether preventive SGLT2 inhibitor administration attenuates the development of metabolic heart disease in a high-fat, high-sucrose diet (HFHSD) mouse model. METHODS: ). CMR assessed epicardial adipose tissue (EAT) volume, fatty acid composition (FAC), proton density fat fraction (PDFF), and T1, and myocardial perfusion, and strain. EAT FAC, PDFF, and T1 were quantified using an inversion-recovery multi-echo gradient-echo sequence and a multi-resonance triglyceride model. EAT volume was quantified using cine images. Myocardial perfusion reserve (MPR) and strain were measured using arterial spin labeling, and displacement encoding with stimulated echoes (DENSE), respectively. Histology and flow cytometry assessed EAT remodeling and macrophage polarization. Myeloid cell NOS2 knockout mice fed an HFHSD exhibited improved adenosine MPR (1.90±0.47 vs 1.39±0.38, p<0.01) compared to floxed controls. CONCLUSIONS: In this obesity-related metabolic heart disease model, EMPA treatment prevents cardiometabolic dysfunction by improving EAT quantity and quality, coronary microvascular function, and diastolic function. These benefits are mediated in part through macrophage NOS2.
No takes yet. Share an insight, caveat, or question.
Bresticker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: